IDEXX Laboratories, Inc. IDXX NASDAQ

IDEXX Laboratories, Inc. (IDXX) generated $1.18B in operating cash flow for fiscal year 2025. After capital expenditures of $124.68M, free cash flow was $1.05B.

Free cash flow margin was 24.5% of revenue. Cash conversion ratio was 1.11x, indicating earnings are backed by cash.

The company returned $1.22B in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (80/100, Pass) — $1.05B (24.5% FCF margin) supports a durable competitive advantage
• INCOME (85/100) — Cash conversion ratio was 1.11x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 71/100 with 5/7 criteria passed.